1910›1910› offers PEGASUS

PEGASUS combines predictive and generative modules around permeability, aqueous solubility, polarity, and target potency for macrocyclic peptide design. The official page identifies a proprietary Permeability Proxy Assay plus quantum-mechanical simulations and Caco-2 and MDCK ground-truth data as parts of the training and evaluation approach.

The product supports both in-silico triage and lead optimization while also describing de-novo design and partner-data fine-tuning. That combination gives the offering several stated workflow entry points without asserting an independently measured advantage beyond the provider's published capabilities.

PEGASUS is an in-silico model, so its utility depends on the quality and scope of the underlying assay, simulation, and permeability data. The official page describes computational modules and partner-data fine-tuning but does not publish prospective clinical validation or a complete experimental success rate.

Access and customization are tied to 1910's platform and co-engineering engagements. The source describes partner proprietary data as a fine-tuning input, which means deployment may require collaboration and data preparation rather than a completely standalone workflow.

PEGASUS targets the design and optimization of drug-like macrocyclic peptides, a workflow where permeability and potency must be considered together. 1910 presents the model for in-silico triage, lead optimization, and de-novo design, linking it to pharmaceutical discovery work.

The product page also describes co-engineering engagements that can fine-tune the model on partner data. That stated collaboration path points toward a partnership-led market approach; the source does not quantify customer count, pricing, or commercial revenue.

PEGASUS is 1910's multimodal AI model for designing and optimizing drug-like macrocyclic peptides. The official product page describes predictive and generative modules trained on 1910's Permeability Proxy Assay together with quantum-mechanical simulations and Caco-2 and MDCK permeability data.

The model is presented for in-silico triage, lead optimization, and de-novo peptide design. 1910 also describes fine-tuning on partner proprietary data through co-engineering engagements, making PEGASUS a computational offering linked to collaborative drug-discovery workflows.